Pharmaceutical Technology on MSN
JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success
The company has made more than 50 deals for its proprietary technology as it looks forward to a potentially “transformative” ...
Agreement grants Lilly rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential disease targets Sangamo to receive an $18 million upfront license fee and is eligible to ...
Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Download Brochure Accurate viral vector characterization in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback